Protagonist Therapeutics Inc. (NASDAQ:PTGX) currently has a daily average trading volume of 1.63M but it saw 1149645 shares traded on Thursday. With a market cap of 1.40B USD, stock’s current market price of $25.36 came rising about 0.96 while comparing to the previous closing price of $25.12. In past 52 weeks, the stock remained buoying in the range of price level as high as $26.87 and as low as $6.91. In the recent trading on the day, stock has struck highest price mark of $26.54 while lowest mark touched by it was $25.34.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Taking a look at 20-day trading activity of Protagonist Therapeutics Inc. (PTGX) gives us an average price of $24.91, while its current price level is -5.62% below from 52-week high level whereas it is 267.00% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $22.89 while that of 200 days or SMA-200 reads an average of $13.96. A closer look into the stock’s movement over the week reveals that its volatility is standing at 4.16% during that period while stretching the period over a month that increases to 5.03%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 56.72 which implies that the stock is in neutral territory.
Over the week, PTGX’s stock price is moving 1.28% up while it is 9.03% when we observe its performance for the past one month. Year-to-date it is 132.45% up and over the past year, the stock is showing an upside performance of 229.35%.
The latest quarterly earnings report issued by the company was for quarter ended 3/30/2023, when its quarterly earnings per share (EPS) of -$0.67 beat the consensus estimate of -$0.73 for the same. For PTGX, analysts are forecasting an EPS-growth rate of 8.10% for current year and estimate for EPS growth in next year is -5.00%. In next quarter, company is expected to be making quarterly sales of $8.33 million as analysts are expecting the sales for current fiscal year at $16.67 million and seeing the company making $19.17 million in sales next year.
Currently, Protagonist Therapeutics Inc.’s total number of outstanding shares is 50.57M with 1.67% of that held by the insiders while 104.10% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -60.90% and return on equity (ROE) at -59.40%. Stock’s beta reads 1.95. Stock has a price to book (P/B) ratio of 5.94 while price to sale or P/S ratio amounts to 1550.62. Its return on asset (ROA) is -51.90% on average.
A filing at the U.S. Securities and Exchange Commission revealed that Vanguard Total Stock Market ETF came shrinking its share ownership by 13.32% in the Protagonist Therapeutics Inc. (PTGX) increasing its stake to 2.94% with control over 0.19 million shares in the company. As per SEC documents, Vanguard Total Stock Market ETF sought 1,655,920 of company’s common stock of worth $37.42 million as per recent closing price of the stock. Vanguard Total Stock Market ETF is not the only institutional holder which restructured its stake in Protagonist Therapeutics Inc., as SPDR S&P Biotech ETF picked 1,322,008 shares of worth $29.88 million to bring its holdings to a total of 23155.0 shares. In the most recent quarter, iShares Russell 2000 ETF came cutting its stake by -1.44% in the company and now holds 0.99 million or 1.76% of the company’s stake having worth of about 22.38 million.
Leave a Reply